Skip to main content
Jafron Biomedical Co.,Ltd. logo

Jafron Biomedical Co.,Ltd. — Investor Relations & Filings

Ticker · 300529 ISIN · CNE100002995 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,842 across all filing types
Latest filing 2019-03-25 Notice of Dividend Amou…
Country CN China
Listing Shenzhen Stock Exchange 300529

About Jafron Biomedical Co.,Ltd.

https://www.jafron.com

Jafron Biomedical Co.,Ltd. specializes in the research, development, and manufacturing of biomaterials and equipment for blood purification. The company is a primary provider of hemoperfusion technology, focusing on the production of adsorbent cartridges designed to remove specific toxins and inflammatory mediators from the bloodstream. Its core product portfolio includes the HA series of hemoperfusion cartridges, which are applied in clinical settings for end-stage renal disease, acute poisoning, critical care, and liver failure. Beyond consumables, the company develops blood purification machines and integrated treatment systems. These solutions target clinical applications in nephrology, intensive care, and hepatology. By leveraging advanced resin adsorption technology, the company provides specialized extracorporeal blood treatment options aimed at improving patient outcomes in complex medical conditions.

Recent filings

Filing Released Lang Actions
2018年度利润分配预案
Notice of Dividend Amount Classification · 95% confidence The document is a profit distribution plan for the fiscal year 2018, detailing the proposed cash dividend per share and the net profit figures audited by an accounting firm. It is an announcement of a dividend proposal to be approved at the upcoming annual general meeting. The document is short (677 characters) and primarily focuses on dividend distribution details rather than presenting full financial statements or comprehensive annual report content. Therefore, it fits best under the category of Notice of Dividend Amount (DIV).
2019-03-25 Chinese
关于公司非经营性资金占用及其他关联资金往来情况汇总表的专项审核报告
Regulatory Filings
2019-03-25 Chinese
中航证券有限公司关于公司2019年度日常关联交易预计的核查意见
Audit Report / Information Classification · 95% confidence The document is titled as an opinion from Zhonghang Securities Co., Ltd. regarding the expected daily related-party transactions of Jianfan Biotechnology Group Co., Ltd. for the year 2019. It includes detailed descriptions of the related-party transactions, their amounts, the related parties, and the compliance with regulatory requirements. The document also contains the independent directors' opinions and the sponsor's verification opinion. The document is a verification or audit opinion on expected related-party transactions, not a full annual report or financial statement. It is not a report publication announcement since it contains substantive content and detailed analysis. The document fits best into the category of Audit Report / Information (AR), as it is a standalone audit opinion on related-party transactions, including compliance with regulations and internal controls, but not a full annual report or interim report. FY 2019
2019-03-25 Chinese
2018年独立董事薪酬的确定以及2019年独立董事薪酬的方案
Remuneration Information Classification · 95% confidence The document details the remuneration of independent directors for the year 2018 and the proposed remuneration plan for 2019. It includes specific salary figures, terms of payment, and mentions that the proposal requires shareholder approval. This content is focused on compensation information for directors rather than a full annual report, proxy solicitation, or remuneration report for all executives. The document is a report on director remuneration, which aligns with the Remuneration Information category (DEF 14A). The document length is short and contains detailed remuneration data, not just an announcement or summary, so it is not a Regulatory Filing or Report Publication Announcement.
2019-03-25 Chinese
关于召开2018年年度股东大会的通知（已取消）
AGM Information Classification · 95% confidence The document is a detailed notice about the convening of the 2018 Annual General Meeting (AGM) of the company, including the meeting date, voting procedures, agenda items, and instructions for shareholders. It includes information about the proposals to be voted on, such as the 2018 annual report, financial statements, profit distribution plan, and other governance matters. The document does not contain the actual annual report or financial statements but rather serves as an official announcement and invitation to the AGM with voting details. Therefore, it fits the category of AGM Information (AGM-R). The document length (5728 characters) and content confirm it is not merely a brief announcement but a full AGM notice with detailed procedural information, supporting a high confidence level.
2019-03-25 Chinese
关于2019年度日常关联交易预计的公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement by the company regarding its expected related party transactions for the fiscal year 2019. It includes details about the nature, estimated amounts, and counterparties of these transactions, as well as opinions from independent directors and the supervisory board. The document does not contain financial statements or comprehensive financial data but rather focuses on disclosure of anticipated related party dealings and compliance with regulatory requirements. It is not an annual report, audit report, or interim financial report. It is also not a voting result, management change, or earnings release. The document fits the category of a regulatory announcement about related party transactions, which is best classified under Regulatory Filings (RNS) as it is a compliance disclosure without substantive financial statements or detailed financial analysis.
2019-03-25 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.